Financial Performance - The company's revenue for Q1 2023 was ¥953,750,622.79, a decrease of 33.31% compared to ¥1,430,136,393.71 in the same period last year[3]. - Net profit attributable to shareholders was ¥41,348,849.29, down 87.49% from ¥330,415,233.13 year-on-year[3]. - Basic earnings per share decreased to ¥0.0911, down 88.68% from ¥0.8050 in the same period last year[3]. - The company's overall operating revenue decreased compared to the same period in 2022, with unconventional business revenue significantly impacted by macroeconomic conditions and industry cycles[12]. - Operating profit for the current period was approximately ¥51.30 million, down from ¥392.53 million in the previous period, reflecting a significant decline[25]. - Total comprehensive income attributable to the parent company was approximately -¥28.24 million, a significant drop from ¥308.27 million in the previous period[26]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥23,177,192.03, a significant improvement of 103.44% compared to a negative cash flow of ¥674,271,200.18 in the previous year[7]. - Cash inflow from financing activities reached ¥115,324,066.00, compared to ¥54,112,075.00 in the prior year[28]. - The net increase in cash and cash equivalents for the period was ¥175,486,107.38, contrasting with a decrease of ¥459,702,988.02 in the previous year[28]. - The company reported a cash payment of ¥42,857,143.00 for dividends, significantly higher than ¥1,788,982.51 in the same quarter last year[28]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,673,806,582.84, a decrease of 4.88% from ¥14,375,513,943.16 at the end of the previous year[3]. - The company's total liabilities decreased to approximately 3.45 billion yuan from 4.15 billion yuan at the beginning of the year, indicating improved financial health[23]. - Accounts receivable decreased significantly to approximately 1.56 billion yuan from 2.21 billion yuan, a reduction of about 29.3%[21]. - The company's inventory remained relatively stable at approximately 715.6 million yuan, slightly down from 717.8 million yuan[22]. Investment and R&D - The company reported a significant increase in investment income, which rose by 359.81% to ¥32,545,471.95 compared to ¥7,077,979.58 in the previous year[6]. - R&D investment as a percentage of operating revenue increased by approximately 4 percentage points compared to the same period last year[13]. - Research and development expenses for the current period were approximately ¥122.05 million, slightly down from ¥131.38 million in the previous period[24]. Business Development and Strategy - The company is actively exploring new business areas, particularly chronic disease management, focusing on cardiovascular and neurodegenerative diseases[13]. - The company launched several new products, including Alzheimer's risk gene testing and cardiovascular disease genetic testing, enhancing its product matrix[12]. - The company aims to leverage its public health platform to expand its international market presence with over 200 overseas product qualifications[12]. - The company plans to strengthen internal management and optimize organizational structure to reduce selling and administrative expenses[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 77,678[8]. - As of April 24, 2023, the controlling shareholder holds 155,247,517 shares, accounting for 37.51% of the total share capital, with 78,370,000 shares pledged, representing 50.48% of their holdings and 18.93% of the total share capital[16]. - The first phase of the employee stock ownership plan involved the sale of 4,000,000 shares, representing 0.9664% of the total share capital, which was completed by January 11, 2023[17]. Social Responsibility - The company has pledged to donate to the Shenzhen Mammoth Public Welfare Foundation as part of its social responsibility initiatives[18]. - The company donated a total of 11 million yuan, with 10 million yuan in cash and 1 million yuan in physical assets, aimed at advancing genetic testing technology and promoting public welfare[19]. Other Notable Events - The "Cloud Data Processing System Upgrade Project" has been delayed from December 31, 2023, to December 31, 2024, due to supply chain issues and increased costs[14]. - The company has adjusted the internal investment structure of the "Shanghai Medical Testing Solution Platform Construction Project," reducing the investment in certain automated equipment while increasing investment in high-throughput sequencers and automated pipetting workstations[14]. - The company has agreed to liquidate its 49% stake in Luzhou Hengkang BGI Biotechnology Co., with an estimated remaining asset value of approximately 3.93 million yuan[18].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 5.2 billion RMB in 2022, representing a year-over-year growth of 15%[8]. - The company reported a significant increase in revenue, achieving a total of 6.6 billion RMB for the year, representing a year-over-year growth of 15%[9]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-over-year growth of 25%[10]. - The company's operating revenue for 2022 was approximately CNY 7.05 billion, an increase of 4.14% compared to CNY 6.77 billion in 2021[18]. - The total revenue for 2022 was approximately ¥7.05 billion, representing a year-over-year increase of 4.14% from ¥6.77 billion in 2021[135]. - The genomics application industry accounted for ¥7.03 billion, or 99.76% of total revenue, with a year-over-year growth of 4.07%[136]. - Revenue from infection prevention research and clinical application services surged by 98.65% to ¥2.30 billion, making up 32.66% of total revenue[136]. - The precision medicine testing comprehensive solution revenue decreased by 25.96% to ¥2.50 billion, which constituted 35.54% of total revenue[136]. - Revenue from direct sales was ¥5.05 billion, accounting for 71.67% of total revenue, with a slight decline of 3.19% compared to the previous year[137]. - The gross profit margin for the genomics application industry was 52.26%, reflecting a decrease of 5.84% year-over-year[137]. Research and Development - The company is investing heavily in R&D, with a budget allocation of 1 billion RMB for the development of new genomic technologies and services in 2023[8]. - Investment in R&D for new technologies increased by 25%, focusing on genomic sequencing and diagnostic tools[9]. - Total R&D investment reached 59.27 million yuan, an increase of 9.31% compared to the previous year[106]. - R&D expenses rose by 9.98% year-on-year to ¥535,786,374.49 in 2022[146]. - The company aims to enhance its product pipeline and increase profitability through continuous product iteration and optimization[148]. Market Expansion and Strategy - BGI anticipates continued growth, projecting a revenue increase of 10-15% for 2023, driven by new product launches and market expansion efforts[8]. - The company plans to expand its market presence internationally, targeting key regions in Europe and North America, aiming for a 25% increase in overseas revenue[8]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share within the next three years[9]. - The company is focusing on expanding its market presence internationally, targeting key regions in Europe and North America for growth opportunities[10]. - The company is exploring strategic acquisitions to enhance its technological capabilities and market reach, with a focus on companies specializing in AI-driven genomic analysis[8]. - A strategic acquisition of a biotech firm was announced, expected to enhance the company's capabilities in personalized medicine[9]. - The company is actively expanding its global presence, with operations in over 100 countries and regions, including partnerships with more than 3,000 overseas medical and research institutions[102]. Product Development and Innovation - BGI has launched a new product line focused on personalized medicine, which is expected to contribute an additional 500 million RMB in revenue in the next fiscal year[8]. - The company is set to launch a new prenatal screening product in Q2 2023, anticipated to capture a significant share of the market[9]. - Research and development efforts have led to the introduction of over 400 new metabolic detection products under the HM400 brand, enhancing the company's product portfolio[11]. - The company has developed a complete product line from carrier screening to pre-implantation genetic testing (PGT), addressing the growing demand for assisted reproductive technology[29]. - The company has launched multiple cancer detection products, including the COLOTECT™ non-invasive colorectal cancer diagnostic test, which has received market access in the EU and five other countries[41]. - The company has developed a comprehensive product line for tumor gene testing, addressing prevention, early screening, diagnosis, and monitoring, enhancing its influence in cancer prevention[41]. - The company has developed a high-throughput pathogen detection product, PMseq®, with an average data volume of 40M-100M reads, significantly higher than competitors' 10M-20M reads, leading to a positive detection rate of 85% when data volume reaches 100M reads[43]. - The company has launched the PMseq Datician pathogen expert analysis system, enhancing the timeliness and accuracy of analysis for hospitals[43]. Financial Health and Profitability - The net profit attributable to shareholders for 2022 was approximately CNY 802.92 million, a decrease of 45.06% from CNY 1.46 billion in 2021[18]. - The basic earnings per share for 2022 was CNY 1.96, a decline of 45.11% compared to CNY 3.56 in 2021[18]. - The company reported a net profit of -51,910,752.73 CNY from non-current asset disposal in 2022, compared to -43,574,897.49 CNY in 2021, indicating an increase in losses[22]. - The company has indicated uncertainty regarding its ability to continue as a going concern based on recent financial performance[18]. - The company reported a significant decrease in cash flow from operating activities in Q1 2022, with a net outflow of approximately CNY 674.27 million[19]. Corporate Governance and Compliance - The company has obtained 224 medical device registration certificates and 293 overseas medical device qualifications, covering 22 countries and regions, ensuring compliance with international standards[85]. - The company emphasizes quality management, having received multiple domestic and international quality awards, and adheres to a comprehensive quality strategy[86]. - The company has established an information security management committee and published over 90 information and data security-related systems to ensure compliance with international security standards[129]. - The company has received multiple awards for its contributions to social responsibility and technological innovation during the reporting period, enhancing its brand recognition[134]. Social Responsibility and Public Health - The company has actively supported public health initiatives globally, gaining widespread social recognition for its efforts[134]. - The company has engaged in social responsibility initiatives, providing free genetic testing and genomic consultation services to over 25,000 individuals during various public health campaigns[131]. - The company has donated a total of 1 million yuan by its executives to support public welfare projects aimed at combating thalassemia and cancer prevention[132]. Talent and Workforce - The proportion of employees with a bachelor's degree or higher is 83%, with 32% holding a master's degree or above[105]. - The company is enhancing its talent competitiveness by focusing on attracting and retaining high-quality talent, with a core management team averaging over 16 years of industry experience[105].

二、公司出席人员 出席本次业绩说明会的公司人员：公司总经理赵立见先生、副总经理兼董事 会秘书徐茜女士、财务总监王玉珏先生、独立董事吴育辉先生、中信证券股份有 限公司保荐代表人黄彪先生。 三、投资者问题征集方式 证券代码：300676 证券简称：华大基因 公告编号：2023-033 深圳华大基因股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司）《2022 年年度报告》及其摘要 已于 2023 年 3 月 31 日披露于巨潮资讯网（http://www.cninfo.com.cn ）。为使投 资者进一步了解公司经营情况，公司定于 2023 年 4 月 7 日在全景网举行 2022 年 度网上业绩说明会。现将具体情况公告如下： 一、召开时间及参与方式 1、召开时间：2023 年 4 月 7 日（星期五）15：00-17：00 2、参与方式：本次年度业绩说明会将采用网络远程的方式举行，投资者可 登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次 ...